Le Lézard
Classified in: Health
Subjects: CCA, ACC, FVT

RiceBran Technologies to Host Q3 2019 Financial Results Conference Call on November 7th at 4:30 PM EST


THE WOODLANDS, Texas, Oct. 31, 2019 /PRNewswire/ -- RiceBran Technologies (NASDAQ: RIBT) (the "Company" or "RBT"), a global leader in the production and marketing of value-added products derived from rice bran and a producer of rice, rice co-product, and barley and oat products, today announced that Mr. Brent Rystrom, Chief Executive Officer & President of RBT, will host a conference call on Thursday, November 7th at 4:30 p.m. EST to discuss the Company's financial results for the third quarter ended September 30, 2019.

Also joining Mr. Rystrom on the call from management will be Todd Mitchell ? Chief Financial Officer.

The call information is as follows:

This call is being webcast by ViaVid and can be accessed at http://public.viavid.com/index.php?id=136914. 

The call will also be available for replay by accessing http://public.viavid.com/index.php?id=136914.

About RiceBran Technologies

RiceBran Technologies is a global leader in the production and marketing of value-added products derived from rice bran as well as a producer of rice, rice co-product, and barley and oat products. The target markets for our products include food and animal nutrition manufacturers and retailers, as well as specialty food, functional food and nutritional supplement manufacturers and retailers. Our highly nutritious and clean label ingredient products derived from rice bran, one of the world's most underutilized food sources, are produced utilizing our proprietary and patented stabilization technology. More information can be found in the Company's filings with the SEC and by visiting our website at http://www.ricebrantech.com.

Investor Contact:
Ascendant Partners, LLC
Richard Galterio
+1-(732)-410-9810
[email protected]

 

SOURCE RiceBran Technologies


These press releases may also interest you

at 11:45
Vertex Announces European Commission Approval for KALYDECO® to Treat Infants With Cystic Fibrosis Ages 1 Month and Older
Vertex Pharmaceuticals today announced that the European Commission has granted approval for the label expansion of KALYDECO® (ivacaftor) for the treatment of infants down to 1 month of age with cystic fibrosis (CF) who have one of the following...

at 11:45
Prostate Cancer Summit: Unveiling the Latest Strategies to Beat Prostate Cancer
Free Virtual Summit Brings Together Experts to Revolutionize Prostate Cancer Care and Treatment Key Takeaways: The Prostate Cancer Summit is a premier virtual event that aims to empower men with practical knowledge and strategies in their fight...

at 11:15
Variantyx Secures $36M Investment As Testing Demand And Market Share Continues To Increase
Variantyx, a leader in molecular diagnostics, announced today that it has secured an additional $36 million in funding from its portfolio of investors which includes Peregrine Ventures, Pitango HealthTech, New Era Capital Partners and Bosch Ventures....

at 11:03
Vajra Coffee Offers Chemical Free Naturally Decaffeinated Coffee
The heart of Vajra Coffee's natural decaffeination process lies in its adoption of the Swiss Water® Process, a natural method that removes 99% of caffeine...

at 11:00
United Imaging Healthcare Releases 2023 ESG Report, Advancing Mission of Equal Healthcare for Alltm
United Imaging Healthcare (SSE:688271) has published its 2023 Environment, Social, and Governance (ESG) Report, reaffirming its mission to bring Equal Healthcare for All. This report highlights the company's advancements in corporate responsibility,...

at 11:00
United Imaging Healthcare releases 2023 annual report, with revenue growth of 23.52%
United Imaging Healthcare (SSE:688271), a global leader in manufacturing advanced medical imaging and radiotherapy equipment, has released their 2023 annual report. The report reveals that the company achieved 11.41 billion CNY in revenue in 2023,...

More news about Health...


News published on and distributed by: